Long-Term CARTITUDE-4 Study Update in MM
October 25th 2024Panelists discuss how data from the long-term CARTITUDE-4 study update in multiple myeloma (MM) highlight the sustained efficacy and safety of ciltacabtagene autoleucel, reinforcing its role as a promising treatment option for patients with lenalidomide-refractory disease.
Overview of CARTITUDE-4: Study Design, Baseline Characteristics, and Efficacy
October 18th 2024Panelists discuss how the CARTITUDE-4 study data provide a comprehensive overview of its design, baseline characteristics, and efficacy outcomes, highlighting the potential of ciltacabtagene autoleucel in improving treatment results for patients with lenalidomide-refractory multiple myeloma.
Impact of CAR T-Cell Therapy in R/R MM
October 11th 2024Panelists discuss how chimeric antigen receptor (CAR) -T-cell therapy has transformed the treatment landscape for relapsed/refractory multiple myeloma (R/R MM), demonstrating remarkable efficacy and offering new hope for patients with limited therapeutic options.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
Telehealth and Treatment Selection: Highlights From an Expert Panel on Multiple Myeloma
June 20th 2023A Satellite Sessions program panel at the University of Texas MD Anderson Cancer Center discusses topics in multiple myeloma including the selection of triplet vs quadruplet treatment regimens and optimizing outcomes in the maintenance setting.